Literature DB >> 27543341

Preconditioning of mesenchymal stem cells with 2,4-dinitrophenol improves cardiac function in infarcted rats.

Irfan Khan1, Anwar Ali2, Muhammad Aleem Akhter1, Nadia Naeem1, Maqsood Ahmed Chotani3, Tuba Mustafa1, Asmat Salim4.   

Abstract

AIMS: The aim of this study is to determine if preconditioning of bone marrow derived mesenchymal stem cells (MSCs) with 2,4-dinitrophenol (DNP) improves survival of transplanted stem cells in a rat model of myocardial infarction (MI), and to asses if this strategy has measurable impact on cardiac function. MAIN
METHODS: MSCs were preconditioned with DNP. In vitro cell adhesion assay and qRT-PCR were performed to analyze the expression of genes involved in cardiomyogenesis, cell adhesion and angiogenesis. MI was produced by occlusion of left anterior descending coronary artery. One million cells were transplanted by intramyocardial injection into the infarcted myocardium. Echocardiography was performed after two and four weeks of cellular transplantation. Hearts were harvested after four weeks and processed for histological analysis. KEY
FINDINGS: DNP treated MSCs adhered to the surface more (p<0.001) as compared to the normal MSCs. Gene expression levels were significantly upregulated in case of DNP treatment. The number of viable MSCs was more (p<0.001) in animals that received DNP treated MSCs, leading to significant improvement in cardiac function. Histological analysis revealed significant reduction in scar formation (p<0.001), maintenance of left ventricular wall thickness (p<0.001), and increased angiogenesis (p<0.01). SIGNIFICANCE: The study evidenced for the first time that MSCs preconditioned with DNP improved cardiac function after transplantation. This can be attributed to improved survival, homing, adhesion, and cardiomyogenic and angiogenic differentiation of DNP treated MSCs in vivo.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiac function; Cell survival; Cell therapy; DNP; Gene expression; Myocardial infarction; Regeneration; Transplantation

Mesh:

Substances:

Year:  2016        PMID: 27543341     DOI: 10.1016/j.lfs.2016.08.014

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  12 in total

Review 1.  State of the field: cellular and exosomal therapeutic approaches in vascular regeneration.

Authors:  Evan Paul Tracy; Virginia Stielberg; Gabrielle Rowe; Daniel Benson; Sara S Nunes; James B Hoying; Walter Lee Murfee; Amanda Jo LeBlanc
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-02-18       Impact factor: 4.733

2.  Autologous Bone Marrow Mononuclear Cells (BMMC)-Associated Anti-Inflammatory Nanoparticles for Cardiac Repair after Myocardial Infarction.

Authors:  Laercio Uemura; Rossana Baggio Simeoni; Paulo André Bispo Machado Júnior; Gustavo Gavazzoni Blume; Luize Kremer Gamba; Murilo Sgarbossa Tonial; Paulo Ricardo Baggio Simeoni; Victoria Stadler Tasca Ribeiro; Rodrigo Silvestre; Katherine Athayde Teixeira de Carvalho; Marcelo Henrique Napimoga; Júlio Cesar Francisco; Luiz Cesar Guarita-Souza
Journal:  J Funct Biomater       Date:  2022-05-13

Review 3.  Pre-Conditioning Methods and Novel Approaches with Mesenchymal Stem Cells Therapy in Cardiovascular Disease.

Authors:  Anthony Matta; Vanessa Nader; Marine Lebrin; Fabian Gross; Anne-Catherine Prats; Daniel Cussac; Michel Galinier; Jerome Roncalli
Journal:  Cells       Date:  2022-05-12       Impact factor: 7.666

Review 4.  Mesenchymal stem cell-derived extracellular vesicles in the failing heart: past, present, and future.

Authors:  Catherine Karbasiafshar; Frank W Sellke; M Ruhul Abid
Journal:  Am J Physiol Heart Circ Physiol       Date:  2021-04-16       Impact factor: 4.733

Review 5.  A brief review: the therapeutic potential of bone marrow mesenchymal stem cells in myocardial infarction.

Authors:  Chi Miao; Mingming Lei; Weina Hu; Shuo Han; Qi Wang
Journal:  Stem Cell Res Ther       Date:  2017-11-02       Impact factor: 6.832

Review 6.  Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies.

Authors:  Nádia de Cássia Noronha; Amanda Mizukami; Carolina Caliári-Oliveira; Juçara Gastaldi Cominal; José Lucas M Rocha; Dimas Tadeu Covas; Kamilla Swiech; Kelen C R Malmegrim
Journal:  Stem Cell Res Ther       Date:  2019-05-02       Impact factor: 6.832

Review 7.  Improved therapeutics of modified mesenchymal stem cells: an update.

Authors:  Dickson Kofi Wiredu Ocansey; Bing Pei; Yongmin Yan; Hui Qian; Xu Zhang; Wenrong Xu; Fei Mao
Journal:  J Transl Med       Date:  2020-01-30       Impact factor: 5.531

Review 8.  Enhancement strategies for mesenchymal stem cells and related therapies.

Authors:  Senthilkumar Alagesan; Jack Brady; Declan Byrnes; Juan Fandiño; Claire Masterson; Sean McCarthy; John Laffey; Daniel O'Toole
Journal:  Stem Cell Res Ther       Date:  2022-02-21       Impact factor: 6.832

Review 9.  Insight in Hypoxia-Mimetic Agents as Potential Tools for Mesenchymal Stem Cell Priming in Regenerative Medicine.

Authors:  Agata Nowak-Stępniowska; Paulina Natalia Osuchowska; Henryk Fiedorowicz; Elżbieta Anna Trafny
Journal:  Stem Cells Int       Date:  2022-03-26       Impact factor: 5.443

Review 10.  Preconditioning influences mesenchymal stem cell properties in vitro and in vivo.

Authors:  Chenxia Hu; Lanjuan Li
Journal:  J Cell Mol Med       Date:  2018-02-01       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.